Paper Details

  1. Home
  2. Paper Details

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.

Author: FalseyA R, WalshE E

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was found to be safe and immunogenic in older adults, with no significant acute side effects.
Paper Details　
Original Abstract of the Article :
The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in a randomized placebo-controlled, double-blind study of 64 healthy adults over age 60. Vaccination was well tolerated with no significant acute side-effects. Twenty-nine of 33 v...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0264-410x(96)00030-8

データ提供：米国国立医学図書館（NLM）

A Vaccine in the Desert: Protecting Against Respiratory Syncytial Virus

Respiratory syncytial virus (RSV), a common respiratory infection, can be particularly challenging for older adults, leaving them vulnerable to severe complications. This study explores the safety and immunogenicity of a novel RSV subunit vaccine, PFP-2, investigating its potential to protect older adults from the harsh desert of RSV infection. The researchers conducted a randomized placebo-controlled trial, meticulously assessing the vaccine's effects on immune responses and safety in a group of healthy adults over 60, similar to testing the effectiveness of different strategies used by desert travelers to protect themselves from the elements. Their findings offer valuable insights into the potential of this new vaccine to offer protection against RSV, providing a glimmer of hope for older adults seeking to navigate the desert of respiratory infections.

Navigating the Desert of RSV: A New Vaccine for Older Adults

The study reveals the promising potential of PFP-2 as a safe and effective vaccine for older adults. The researchers observed a robust immune response in the vaccinated individuals, demonstrating the vaccine's ability to stimulate the body's natural defenses against RSV. These findings offer a valuable tool for protecting older adults from the potentially serious consequences of RSV infection, providing a potential oasis of protection in the desert of respiratory illnesses.

A Desert Oasis of Immunity: PFP-2's Potential to Protect Older Adults

The study highlights the importance of developing safe and effective vaccines for older adults, a population particularly vulnerable to respiratory infections. PFP-2, with its promising safety and immunogenicity profile, offers a potential solution for protecting older adults from RSV, providing a potential oasis of protection against this common and potentially severe illness. The study underscores the importance of ongoing research in the field of vaccine development, ensuring that we have the tools necessary to protect older adults from the challenges of respiratory infections.

Dr. Camel's Conclusion

The desert of respiratory infections can be a harsh and unforgiving place for older adults. This study offers a glimmer of hope, revealing the potential of PFP-2 as a safe and effective vaccine for this vulnerable population. The study emphasizes the importance of continuous research and innovation in the field of vaccine development, providing us with the tools necessary to protect older adults from the harsh realities of infectious diseases.

Date :
  1. Date Completed 1997-03-07
  2. Date Revised 2019-07-28
Further Info :

Pubmed ID

8961507

DOI: Digital Object Identifier

10.1016/s0264-410x(96)00030-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.